ArticleSpringerPlus2013
RNA blood levels of osteopontin splice variants are cancer markers.
Article in SpringerPlus, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Meta-analysis of Osteopontin splice variants in cancer.BMC cancer · 2023Pooled it
- Overexpression of Osteopontin-a and Osteopontin-c Splice Variants Are Worse Prognostic Features in Colorectal Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- OPN Promotes Cell Proliferation and Invasion through NF-Genetics research · 2022Article
- Periostin in Allergy and Inflammation.Frontiers in immunology · 2021Review
- Prognostic significance of serum osteopontin levels in small cell lung cancer.BMC pulmonary medicine · 2020Article
- Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis.British journal of cancer · 2018Article
- Nuclear osteopontin-c is a prognostic breast cancer marker.British journal of cancer · 2015Article
- The downregulation of OPN inhibits proliferation and migration and regulate activation of Erk1/2 in ECA-109 cells.International journal of clinical and experimental medicine · 2015Article
- SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.World journal of gastroenterology · 2014Review
- Role of osteopontin in the pathophysiology of cancer.Matrix biology : journal of the International Society for Matrix Biology · 2014Review
- Osteopontin-a alters glucose homeostasis in anchorage-independent breast cancer cells.Cancer letters · 2014Article
- Malignant mesothelioma: development to therapy.Journal of cellular biochemistry · 2014Article
- Transgenic mammary epithelial osteopontin (spp1) expression induces proliferation and alveologenesis.Genes & cancer · 2013Article
- Osteopontin in pancreatic cancer: A systematic review.Medicine internationalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDespite a sizeable and continuously growing literature on osteopontin and cancer the molecule has not yet found entry into clinical diagnostics. Our identification of spliced variants that are more specific for cancer than the full-length transcript has opened new possibilities for reaching this goal.
methodsHere we have developed a real-time RT-PCR blood test and evaluated it in a pilot study of breast, lung, pancreatic, gynecologic, and other cancers, compared to non-cancer controls.
resultsOsteopontin-b was increased in lung cancers and pancreatic cancers. When applying a cutoff of 2 standard deviations above normal, elevation in osteopontin-b transcripts detected over 40% of lung cancers. Osteopontin-c was increased in gynecologic and pancreatic cancers. Elevation in osteopontin-c of 2 standard deviations above the normal mean value also detected a fraction of breast cancers and lung cancers, suggesting heterogeneity within those types of tumors. Specifically, breast carcinomas were associated with significantly higher levels of osteopontin-c mRNA in the blood than carcinomas in situ. In lung cancer patients, the osteopontin-c blood RNA levels had an increasing trend with tumor grade.
conclusionsOsteopontin-b and -c in the blood are biomarkers for distinct cancers. Our investigations may have bearing on cancer screening and diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.